Best Probiotic Strains by Condition: IBS, Bloating, Immunity, and Mood

At a Glance

Best Probiotic Strains: Why the Strain Number Matters

The single most important concept in probiotic science is one that most consumers — and many healthcare providers — do not understand: probiotic effects are strain-specific.

Lactobacillus rhamnosus GG has robust evidence for preventing antibiotic-associated diarrhea. Lactobacillus rhamnosus HN001 has evidence for eczema prevention in infants. These are different strains of the same species — and their clinical effects do not overlap. Buying a product that says “Lactobacillus rhamnosus” without a strain designation tells you nothing about what clinical evidence applies.

This is something that makes me genuinely frustrated about the probiotic market. Billions of dollars are spent on products that list species but not strains, making it impossible to match the product to the evidence. Let me walk you through what actually works, strain by strain.

Condition-Specific Strain Recommendations

IBS and Bloating

IBS is the condition with the most probiotic research, and the evidence clearly points to specific strains:

Bifidobacterium infantis 35624 (Bifantis/Align)

• Evidence: The strongest single-strain evidence for IBS. Whorwell et al. conducted a large, well-designed RCT showing significant improvement in abdominal pain, bloating, and bowel dysfunction at 1 x 10^8 CFU/day over 4 weeks (1).
• Dose: 1 billion CFU/day
• Mechanism: Normalizes the IL-10/IL-12 ratio (anti-inflammatory to pro-inflammatory balance) and reduces intestinal permeability
• Best for: IBS with bloating, general IBS symptom relief

Lactobacillus plantarum 299v (Jarrow Ideal Bowel Support)

• Evidence: Multiple RCTs for IBS, particularly IBS with bloating. Ducrotte et al. showed significant reduction in abdominal pain and bloating at 10 billion CFU/day.
• Dose: 10 billion CFU/day
• Mechanism: Reduces gas production, improves intestinal barrier function
• Best for: IBS-bloating dominant, functional bloating

Saccharomyces boulardii CNCM I-745 (Florastor)

• Evidence: The most-studied probiotic yeast. Multiple meta-analyses confirm efficacy for IBS-D (diarrhea-dominant IBS).
• Dose: 500 mg (250 mg twice daily)
• Mechanism: Degrades Clostridium difficile toxin receptors, enhances secretory IgA, stimulates brush border enzymes
• Best for: IBS-D, antibiotic-associated diarrhea, traveler’s diarrhea, C. difficile prevention

Immune Support

Lactobacillus rhamnosus GG (LGG)

• Evidence: The single most-studied probiotic strain in the world. Hundreds of clinical trials. Prevents antibiotic-associated diarrhea (NNT = 13), reduces respiratory infection duration by 1-2 days in children, and enhances innate immune responses.
• Dose: 10-20 billion CFU/day
• Mechanism: Enhances macrophage phagocytosis, increases secretory IgA, modulates Th1/Th2 balance
• Best for: General immune resilience, antibiotic-associated diarrhea prevention

Lactobacillus rhamnosus HN001

• Evidence: RCTs in pregnant women and infants showed reduced eczema incidence (by 50% at 4 years follow-up in the New Zealand study). Also improves postpartum depression and anxiety symptoms.
• Dose: 6 billion CFU/day
• Best for: Pregnancy, infant immune programming, atopic disease prevention

Mood and Anxiety (Psychobiotics)

Lactobacillus helveticus R0052 + Bifidobacterium longum R0175 (Cerebiome/Probio’Stick)

• Evidence: The most studied psychobiotic combination. Messaoudi et al. conducted a double-blind RCT showing significant reductions in perceived stress, anxiety, and cortisol levels after 30 days. Validated by the Hopkins Symptom Checklist, Hospital Anxiety and Depression Scale, and urinary free cortisol measurement (2).
• Dose: 3 billion CFU/day (combined)
• Mechanism: Gut-brain axis modulation via vagal nerve signaling, reduced intestinal permeability (less LPS translocation), HPA axis modulation
• Best for: Stress-related anxiety, mild-moderate mood issues, cortisol management

Lactobacillus plantarum PS128

• Evidence: Emerging data for depression and autism spectrum disorder. A 2019 RCT showed improved emotional and behavioral outcomes in children with ASD.
• Dose: 30 billion CFU/day
• Best for: Research-stage psychobiotic with promising neuropsychiatric data

Vaginal Health

Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14 (Jarrow Fem-Dophilus)

• Evidence: Multiple RCTs showing restoration of healthy vaginal flora, prevention of bacterial vaginosis recurrence, and reduction of urinary tract infections.
• Dose: 2 billion CFU/day (oral administration; they colonize vaginally via GI transit)
• Mechanism: Produce hydrogen peroxide and bacteriocins that inhibit pathogenic bacteria; restore Lactobacillus dominance in vaginal microbiome
• Best for: Recurrent bacterial vaginosis, recurrent UTI prevention

Antibiotic Recovery

Saccharomyces boulardii CNCM I-745 — take throughout the antibiotic course and for 2 weeks after. As a yeast, it is unaffected by antibacterial antibiotics.

Lactobacillus rhamnosus GG — take 2+ hours separated from antibiotic doses to minimize direct killing.

Combination approach: S. boulardii during antibiotics, then transition to a multi-strain product (LGG + B. infantis 35624 + L. plantarum 299v) for 4 weeks post-antibiotic.

The Strain Selection Framework

What About Multi-Strain Products?

Many popular probiotic products contain 10-15 different strains. The assumption is “more is better.” The evidence does not clearly support this assumption.

The case for single/dual-strain products:

• The clinical evidence is strain-specific. Most positive RCTs used single strains or specific combinations.
• Strain interactions within a product are poorly understood. Some strains may compete with or inhibit others.
• You know exactly what you are taking and can match it to the evidence.

The case for multi-strain products:

• Broader coverage of the microbiome may provide resilience benefits not captured in condition-specific trials.
• Some multi-strain products (VSL#3/Visbiome) have their own clinical trial evidence as complete formulations.
• Ecological diversity may be inherently beneficial for gut health.

My position: Match the strain to your specific condition using the evidence above. If you have no specific condition and want general gut health support, a well-formulated multi-strain product with at least some evidence-backed strains (LGG, B. infantis 35624, L. plantarum 299v) at adequate doses is reasonable.

For guidance on CFU counts and what to look for on a label, see my guide on how to choose a probiotic. For the broader ecosystem including prebiotics and postbiotics, see probiotics vs. prebiotics vs. postbiotics.

Safety and Considerations

Probiotics are generally very safe for immunocompetent individuals. Rare concerns include:

• Immunocompromised patients: Avoid live probiotics in severely immunosuppressed individuals (transplant recipients, neutropenic patients, central venous catheter use). S. boulardii has caused fungemia in ICU patients with central lines.
• SIBO: Some individuals with small intestinal bacterial overgrowth may initially worsen with Lactobacillus-dominant probiotics. S. boulardii may be better tolerated.
• Histamine sensitivity: Some Lactobacillus strains (L. casei, L. bulgaricus) produce histamine and may worsen symptoms in histamine-intolerant individuals. L. rhamnosus GG and B. infantis are generally low-histamine.

The Bottom Line

Probiotic selection should be evidence-based and strain-specific. A product listing “Lactobacillus acidophilus” without a strain number is clinically meaningless — you cannot match it to any trial. The strongest evidence exists for S. boulardii for diarrheal conditions, L. rhamnosus GG for immune support, B. infantis 35624 for IBS, and the Cerebiome combination for mood. Choose your strain based on your condition, verify the strain designation on the product label, and give it 4-8 weeks. This is what the research actually says.

References

1. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. American Journal of Gastroenterology. 2006;101(7):1581-1590. doi:10.1111/j.1572-0241.2006.00734.x

2. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. British Journal of Nutrition. 2011;105(5):755-764. doi:10.1017/S0007114510004319

3. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969. doi:10.1001/jama.2012.3507